Rigshospitalet, dep. 2112
Copenhagen, 2100, Denmark
NCT Number: NCT01142115
The purpose of this study is to evaluate the safety of a new developed catheter in comparison with an catheter on the market. The study is randomised.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Not applicable
Copenhagen, 2100, Denmark
Intermittent catheterization is the preferred method for emptying the bladder in patients with spinal cord injury and neurogenic bladder dysfunction.
Coloplast has developed a new intermittent catheter. In this investigation this new test catheter will be compared with SpeediCath by assessing discomfort and pain associated with catheterization of healthy men. The reason for choosing healthy men is that many catheter users do not have full feeling in their urethra and therefore can not assess the discomfort.
Healthy men who are ≥ 18 years and have no signs of urinary tract infection and do not have abnormalities, disease or have had operational interventions in the urinary tract will be included. They are recruited through advertisements on the website www.forsoegsperson.dk.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
intermittent catheterisation
Other names: Intermittent catheter,
intermittent catheterisation
Other names: Intermittent catheter
Time frame: 10 minutes after each catheterisation at visit 1 and at visit 2 which is 5-25 days after visit 1
Outcome measured on a 10 cm Visual Analog Scale ranging from "no discomfort" (0cm) to "worst thinkable discomfort" (10cm).
Time frame: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
After each catheterization subjects were asked if they felt any irritation during voiding with answer option yes or no.
Yes - they experienced irritation. No - they did not experience irritation.
Time frame: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
After each catheterization the nurse who conducted the catheterization answered how the catheter insertion had been.
There were 5 answer categories: very difficult - difficult - neither easy nor difficult - easy - very easy
Time frame: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
After each catheterization the nurse who conducted the catheterization answered how the catheter withdrawal had been.
There were 5 answer categories: very difficult - difficult - neither easy nor difficult - easy - very easy
Time frame: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
Visual blood observed on the catheter or in the urine in connection to catheterization.
The nurse who conducted the catheterization could answer yes or no as follows:
Yes = visible blood observed. No = no visible blood observed.
Time frame: 2 hours after catheterisation at visits 1 and 2
Negative or positive result on a multistix urin analysis.
Negative haematuria: 10 erythrocytes/microliter or less. Positive haematuria: above 10 erythrocytes/microliter.
Coloplast A/S
Industry
Comparative Study of Two Different Urine Catheters.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07507331
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsNCT05433064
Central Nervous System Diseases, Nervous System Diseases
Hualien City, Taiwan
View Trial DetailsNCT07717606
Central Nervous System Diseases, Conus Medullaris Injury
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07706517
Brain Damage, Chronic, Brain Diseases
Saint-Etienne, France
View Trial Details